NRx Pharmaceuticals names Glenn Tyson as first chief commercial officer
PUBT · 1d ago
Share
Listen to the news
- NRx Pharmaceuticals appointed Glenn Tyson as its first chief commercial officer.
- Tyson previously held senior commercial roles at GSK, Indivior, Transcend Therapeutics.
- NRx plans to build market access, distribution, sales, marketing ahead of expected approval of its preservative-free ketamine ANDA.
- Commercial push also targets near-term New Drug Application submission to expand IV ketamine labeling to depression, suicidality.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604130700PRIMZONEFULLFEED9688165) on April 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved